Concepts (191)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Erythrocyte Transfusion | 19 | 2024 | 75 | 3.350 |
Why?
|
| Anemia | 15 | 2022 | 117 | 2.290 |
Why?
|
| Critical Illness | 19 | 2022 | 332 | 2.160 |
Why?
|
| Intensive Care Units, Pediatric | 15 | 2020 | 66 | 1.580 |
Why?
|
| Fluid Therapy | 4 | 2018 | 53 | 1.530 |
Why?
|
| Water-Electrolyte Imbalance | 2 | 2020 | 11 | 1.310 |
Why?
|
| Child | 30 | 2023 | 4306 | 1.200 |
Why?
|
| Respiration, Artificial | 8 | 2023 | 294 | 1.050 |
Why?
|
| Acute Lung Injury | 2 | 2023 | 41 | 1.030 |
Why?
|
| Neuromuscular Blockade | 2 | 2023 | 9 | 0.970 |
Why?
|
| Water-Electrolyte Balance | 3 | 2020 | 19 | 0.890 |
Why?
|
| Critical Care | 17 | 2022 | 411 | 0.870 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 53 | 0.850 |
Why?
|
| Ventilator-Induced Lung Injury | 2 | 2013 | 11 | 0.840 |
Why?
|
| Hemostatics | 1 | 2022 | 27 | 0.800 |
Why?
|
| Hemoglobins | 4 | 2023 | 139 | 0.800 |
Why?
|
| Delirium | 1 | 2023 | 56 | 0.800 |
Why?
|
| Respiratory Insufficiency | 3 | 2019 | 152 | 0.780 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 77 | 0.610 |
Why?
|
| Phlebotomy | 2 | 2017 | 8 | 0.540 |
Why?
|
| Infant | 11 | 2022 | 1527 | 0.520 |
Why?
|
| Child, Preschool | 11 | 2020 | 1839 | 0.500 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2015 | 9 | 0.500 |
Why?
|
| Evidence-Based Medicine | 13 | 2022 | 452 | 0.450 |
Why?
|
| Humans | 36 | 2024 | 59527 | 0.420 |
Why?
|
| Hemorrhage | 3 | 2022 | 277 | 0.420 |
Why?
|
| Platelet Transfusion | 4 | 2022 | 13 | 0.350 |
Why?
|
| Infant, Newborn | 7 | 2022 | 1311 | 0.330 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2018 | 14 | 0.310 |
Why?
|
| Sepsis | 2 | 2022 | 281 | 0.270 |
Why?
|
| Pediatrics | 2 | 2020 | 266 | 0.260 |
Why?
|
| Self Report | 2 | 2019 | 366 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 703 | 0.250 |
Why?
|
| Adolescent | 7 | 2020 | 5932 | 0.240 |
Why?
|
| Blood Banks | 1 | 2024 | 9 | 0.230 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2022 | 5 | 0.200 |
Why?
|
| Liver Failure, Acute | 1 | 2022 | 16 | 0.200 |
Why?
|
| Heart Defects, Congenital | 2 | 2023 | 96 | 0.190 |
Why?
|
| Transfusion Reaction | 2 | 2018 | 46 | 0.190 |
Why?
|
| Consensus | 2 | 2023 | 194 | 0.190 |
Why?
|
| Neoplasms | 2 | 2022 | 1243 | 0.170 |
Why?
|
| Liver Transplantation | 1 | 2022 | 189 | 0.170 |
Why?
|
| Education, Distance | 1 | 2020 | 34 | 0.160 |
Why?
|
| Thalassemia | 1 | 2018 | 4 | 0.160 |
Why?
|
| Anemia, Hemolytic | 1 | 2018 | 11 | 0.160 |
Why?
|
| Shock, Hemorrhagic | 1 | 2018 | 19 | 0.150 |
Why?
|
| Shock | 1 | 2018 | 31 | 0.150 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 23 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 66 | 0.150 |
Why?
|
| Health Personnel | 1 | 2021 | 341 | 0.150 |
Why?
|
| Blood Transfusion | 1 | 2018 | 148 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 99 | 0.140 |
Why?
|
| Male | 9 | 2020 | 27578 | 0.140 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 42 | 0.140 |
Why?
|
| Cohort Studies | 2 | 2014 | 2442 | 0.140 |
Why?
|
| Female | 9 | 2020 | 30924 | 0.130 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 126 | 0.130 |
Why?
|
| Diet Therapy | 1 | 2015 | 14 | 0.120 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 56 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 674 | 0.120 |
Why?
|
| Conscious Sedation | 1 | 2015 | 51 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2015 | 83 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2020 | 679 | 0.120 |
Why?
|
| Erythrocyte Count | 3 | 2018 | 14 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 2470 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 296 | 0.110 |
Why?
|
| Incidence | 2 | 2020 | 1238 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2015 | 6011 | 0.110 |
Why?
|
| Pain Management | 1 | 2015 | 145 | 0.110 |
Why?
|
| Acute Disease | 1 | 2015 | 659 | 0.110 |
Why?
|
| Length of Stay | 1 | 2016 | 771 | 0.100 |
Why?
|
| Boston | 1 | 2014 | 331 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2016 | 886 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2012 | 108 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2020 | 727 | 0.100 |
Why?
|
| Kainic Acid | 3 | 2002 | 7 | 0.100 |
Why?
|
| Blood Component Transfusion | 2 | 2022 | 8 | 0.100 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 19 | 0.100 |
Why?
|
| Plasma | 2 | 2022 | 33 | 0.100 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 53 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2012 | 254 | 0.090 |
Why?
|
| Age Distribution | 1 | 2012 | 261 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 715 | 0.090 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1449 | 0.080 |
Why?
|
| Patient Safety | 1 | 2012 | 243 | 0.080 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 141 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 197 | 0.070 |
Why?
|
| Risk Factors | 2 | 2015 | 5017 | 0.060 |
Why?
|
| Cerebellum | 3 | 2002 | 94 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 442 | 0.060 |
Why?
|
| Neurotoxins | 2 | 2002 | 20 | 0.060 |
Why?
|
| Neurons | 2 | 2002 | 859 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2012 | 1915 | 0.060 |
Why?
|
| Calcium Channels, L-Type | 2 | 2002 | 25 | 0.060 |
Why?
|
| Receptors, Glutamate | 1 | 2002 | 18 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2002 | 56 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2020 | 3101 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2002 | 202 | 0.050 |
Why?
|
| Research | 1 | 2022 | 191 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2000 | 84 | 0.040 |
Why?
|
| Decision Making | 1 | 2023 | 390 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2002 | 192 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 259 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 95 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 149 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 1999 | 19 | 0.040 |
Why?
|
| Ion Channel Gating | 1 | 1999 | 44 | 0.040 |
Why?
|
| Simulation Training | 1 | 2020 | 58 | 0.040 |
Why?
|
| Carboxypeptidases | 1 | 1999 | 7 | 0.040 |
Why?
|
| IgA Deficiency | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2018 | 7 | 0.040 |
Why?
|
| Calcium Channels | 1 | 1999 | 96 | 0.040 |
Why?
|
| Vital Signs | 1 | 2018 | 11 | 0.040 |
Why?
|
| Blood Gas Analysis | 1 | 2018 | 34 | 0.040 |
Why?
|
| Decision Trees | 1 | 2018 | 51 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 189 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 75 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 1999 | 191 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4332 | 0.040 |
Why?
|
| Hemoglobinometry | 1 | 2017 | 2 | 0.040 |
Why?
|
| Missouri | 1 | 2017 | 12 | 0.040 |
Why?
|
| Pediatric Nursing | 1 | 2017 | 11 | 0.040 |
Why?
|
| Utilization Review | 1 | 2017 | 31 | 0.040 |
Why?
|
| Hematocrit | 1 | 2017 | 33 | 0.040 |
Why?
|
| Blood Volume | 1 | 2017 | 42 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 42 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 1095 | 0.040 |
Why?
|
| Inservice Training | 1 | 2017 | 83 | 0.030 |
Why?
|
| Nifedipine | 3 | 2002 | 15 | 0.030 |
Why?
|
| Calcium Channel Blockers | 3 | 2002 | 56 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 827 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1572 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 148 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 2015 | 48 | 0.030 |
Why?
|
| Pediatric Obesity | 1 | 2016 | 93 | 0.030 |
Why?
|
| Adult | 2 | 2023 | 15791 | 0.030 |
Why?
|
| New England | 1 | 2015 | 268 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 118 | 0.030 |
Why?
|
| Cell Survival | 3 | 2002 | 557 | 0.030 |
Why?
|
| Overweight | 1 | 2016 | 247 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 926 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 774 | 0.030 |
Why?
|
| Rats | 3 | 2002 | 1913 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2002 | 2104 | 0.020 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2002 | 31 | 0.020 |
Why?
|
| Biometry | 1 | 2008 | 11 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 3579 | 0.020 |
Why?
|
| Bias | 1 | 2008 | 106 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 250 | 0.020 |
Why?
|
| Patients | 1 | 2008 | 102 | 0.020 |
Why?
|
| Calcium | 2 | 2000 | 556 | 0.020 |
Why?
|
| Research Design | 1 | 2008 | 567 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2002 | 47 | 0.010 |
Why?
|
| Electron Transport | 1 | 2002 | 35 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2002 | 230 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 253 | 0.010 |
Why?
|
| Iron | 1 | 2002 | 144 | 0.010 |
Why?
|
| Spider Venoms | 1 | 2000 | 2 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2000 | 9 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2000 | 8 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 2000 | 39 | 0.010 |
Why?
|
| Receptors, AMPA | 1 | 2000 | 41 | 0.010 |
Why?
|
| Cell Death | 1 | 2002 | 268 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 195 | 0.010 |
Why?
|
| Neuroprotective Agents | 1 | 2000 | 72 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2000 | 168 | 0.010 |
Why?
|
| Dizocilpine Maleate | 1 | 1999 | 6 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1999 | 17 | 0.010 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1999 | 12 | 0.010 |
Why?
|
| Ryanodine | 1 | 1999 | 10 | 0.010 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1999 | 26 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1999 | 21 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 1999 | 52 | 0.010 |
Why?
|
| Sodium | 1 | 1999 | 60 | 0.010 |
Why?
|
| Sucrose | 1 | 1999 | 29 | 0.010 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 1999 | 8 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1999 | 134 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 809 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1999 | 190 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 1999 | 98 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 138 | 0.010 |
Why?
|
| Mitochondria | 1 | 2002 | 337 | 0.010 |
Why?
|
| Animals | 3 | 2002 | 19663 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 255 | 0.010 |
Why?
|
| Zinc | 1 | 1999 | 90 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1999 | 376 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 341 | 0.010 |
Why?
|
| Insulin | 1 | 2000 | 687 | 0.010 |
Why?
|
| Binding Sites | 1 | 1999 | 875 | 0.010 |
Why?
|
| Apoptosis | 1 | 1999 | 1039 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2000 | 2891 | 0.010 |
Why?
|